Astellas Pharma gets global rights to an Evopoint Biosciences antibody drug conjugate that targets Claudin 18.2. Last year, Astellas’s antibody drug Vyloy became the first FDA-approved therapy for this target.Astellas Pharma already has the first FDA approval for a therapy that goes after Claudin 18.2, a protein whose overexpression on the surface of cells in […]
